PT  - JOURNAL ARTICLE
AU  - VLADISLAV TRESKA
AU  - VACLAV LISKA
AU  - JAKUB FICHTL
AU  - DANIEL LYSAK
AU  - HYNEK MIRKA
AU  - JAN BRUHA
AU  - PETR DURAS
AU  - INKA TRESKOVA
AU  - JAKUB NAHLIK
AU  - VACLAV SIMANEK
AU  - ONDREJ TOPOLCAN
TI  - Portal Vein Embolisation with Application of Haematopoietic Stem Cells in Patients with Primarily or Non-resectable Colorectal Liver Metastases
DP  - 2014 Dec 01
TA  - Anticancer Research
PG  - 7279--7285
VI  - 34
IP  - 12
4099  - http://ar.iiarjournals.org/content/34/12/7279.short
4100  - http://ar.iiarjournals.org/content/34/12/7279.full
SO  - Anticancer Res2014 Dec 01; 34
AB  - Background: Insufficient future liver remnant volume (FLRV) is the main cause of low resectability of liver metastases from colorectal cancer (CLMs). One option for enhancing FLVR growth is the use of portal vein embolisation (PVE) with the application of autologous haematopoietic stem cells (HSCs). Patients and Methods: PVE with the application of HSCs was used in 11 patients (group 1) with primarily non-resectable CLMs due to insufficient FLRV without signs of extrahepatic metastases. The control group (group 2) consisted of 14 patients in whom only PVE was performed. We evaluated the product quality, FLRV growth, CLM volume, median survival and progression-free survival (PFS). Results: Product quality was achieved in all collections. In all group-I patients, sufficient FLRV growth occurred within three weeks. In the first and second weeks, FLRV increased optimally in most patients (p<0.006). In 13 out of the 14 group-2 patients, optimum FLVR growth was observed within three weeks following PVE (p<0.002). More rapid FLVR growth was observed in group 1 patients (p<0.01). CLM volume was significantly increased in both the group-2 (p<0.0005) and group-1 (p<0.008) patients at the time of liver resection. There was no significant difference in the growth of the CLM volume between the groups (p<0.18). The median survival was 7.3 and 6.8 months for group 1 and 2 patients, respectively, and the two-year PFS was 28% and 22% (p<0.18), respectively. Conclusion: PVE with HSC application is a promising method for effectively stimulating FLRV growth in patients with primarily non-resectable CLMs.